0001474064-12-000030.txt : 20120209 0001474064-12-000030.hdr.sgml : 20120209 20120209170609 ACCESSION NUMBER: 0001474064-12-000030 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20120207 FILED AS OF DATE: 20120209 DATE AS OF CHANGE: 20120209 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Nader Francois CENTRAL INDEX KEY: 0001365343 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-23272 FILM NUMBER: 12588266 MAIL ADDRESS: STREET 1: 550 HILLS DRIVE CITY: BEDMINSTER STATE: NJ ZIP: 07921 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: NPS PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000890465 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 870439579 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 550 HILLS DRIVE CITY: BEDMINSTER STATE: NJ ZIP: 07921 BUSINESS PHONE: (908) 450-5300 MAIL ADDRESS: STREET 1: 550 HILLS DRIVE CITY: BEDMINSTER STATE: NJ ZIP: 07921 4 1 edgar.xml PRIMARY DOCUMENT X0304 4 2012-02-07 0000890465 NPS PHARMACEUTICALS INC NPSP 0001365343 Nader Francois 550 HILLS DRIVE BEDMINSTER NJ 07921 1 1 0 0 President, CEO and Director Common Stock 2012-02-07 4 A 0 60900 0 A 60900 D Common Stock 2012-02-07 4 A 0 60900 0 A 60900 D Stock Option 8.21 2012-02-07 4 A 0 107700 0 A 2022-02-07 Common Stock 107700 107700 D Restricted Stock Units awarded under the 2005 Omnibus Incentive Plan that will be settled in NPS Common Stock as follows: (i) one third will vest on the first anniversary of date of grant, one third on the second anniversary of date of grant, and one third on the third anniversary of date of grant. Restricted Stock Units awarded under the 2005 Omnibus Incentive Plan that will be settled in NPS Common Stock as follows: one half will vest upon FDA approval of GATTEX, and one half will vest upon FDA approval of NATPARA, with no shares being able to be earned after 7/31/14. Stock options granted under the 2005 Omnibus Incentive Plan. The options become exercisable based on the following vesting schedule: 25% on the first anniversary of the grant and 6.25% every three months thereafter. /s/ Francois Nader, by Edward Stratemeier as Attorney-in-Fact 2012-02-09